[{"address1": "7-11 boulevard Haussmann", "city": "Paris", "zip": "75009", "country": "France", "phone": "33 1 53 83 09 63", "website": "https://www.abivax.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "ABIVAX Soci\u00e9t\u00e9 Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Soci\u00e9t\u00e9 Anonyme was incorporated in 2013 and is headquartered in Paris, France.", "fullTimeEmployees": 61, "companyOfficers": [{"maxAge": 1, "name": "Mr. Marc M. P. de Garidel M.B.A.", "age": 65, "title": "CEO & Director", "yearBorn": 1958, "fiscalYear": 2023, "totalPay": 887429, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Philippe  Pouletty M.D., Ph.D.", "age": 65, "title": "Founder & Director", "yearBorn": 1958, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Didier  Blondel", "age": 59, "title": "EVP, CFO & Board Secretary", "yearBorn": 1964, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Didier  Scherrer Ph.D.", "age": 53, "title": "Chief Scientific Officer", "yearBorn": 1970, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Patrick  Malloy", "title": "Senior Vice President of Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Ida  Hatoum", "age": 48, "title": "Chief People & Compliance Officer", "yearBorn": 1975, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Pierre  Courteille M.B.A.", "age": 54, "title": "Chief Business Officer", "yearBorn": 1969, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jerome  Denis Ph.D.", "title": "Executive Vice President of Process Development & Manufacturing", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Michael  Ferguson B.S., M.B.A.", "age": 45, "title": "Chief Commercial Officer", "yearBorn": 1978, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Ana  Sharma M.P.H.", "title": "VP & Global Head of Quality", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 10, "boardRisk": 9, "compensationRisk": 10, "shareHolderRightsRisk": 7, "overallRisk": 10, "governanceEpochDate": 1725148800, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 12.26, "open": 12.225, "dayLow": 12.095, "dayHigh": 12.54, "regularMarketPreviousClose": 12.26, "regularMarketOpen": 12.225, "regularMarketDayLow": 12.095, "regularMarketDayHigh": 12.54, "beta": 1.452, "forwardPE": -3.861635, "volume": 135709, "regularMarketVolume": 135709, "averageVolume": 69782, "averageVolume10days": 69850, "averageDailyVolume10Day": 69850, "bid": 12.23, "ask": 12.43, "bidSize": 200, "askSize": 100, "marketCap": 804498368, "fiftyTwoWeekLow": 7.995, "fiftyTwoWeekHigh": 17.02, "priceToSalesTrailing12Months": 179.05595, "fiftyDayAverage": 12.2036, "twoHundredDayAverage": 12.804365, "currency": "USD", "enterpriseValue": 584843520, "floatShares": 26137884, "sharesOutstanding": 62917700, "sharesShort": 166473, "sharesShortPriorMonth": 57220, "sharesShortPreviousMonthDate": 1721001600, "dateShortInterest": 1723680000, "sharesPercentSharesOut": 0.0026, "heldPercentInstitutions": 0.44692, "shortRatio": 1.25, "impliedSharesOutstanding": 65512900, "bookValue": 3.115, "priceToBook": 3.942215, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -147740000, "trailingEps": -3.8, "forwardEps": -3.18, "enterpriseToRevenue": 130.168, "enterpriseToEbitda": -4.596, "52WeekChange": 0.47710848, "SandP52WeekChange": 0.24014747, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "ABVX", "underlyingSymbol": "ABVX", "shortName": "Abivax SA", "longName": "ABIVAX Soci\u00e9t\u00e9 Anonyme", "firstTradeDateEpochUtc": 1697808600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "da2a4204-bbb1-38b0-9537-637cf418cbe0", "messageBoardId": "finmb_256839883", "gmtOffSetMilliseconds": -14400000, "currentPrice": 12.28, "targetHighPrice": 53.03, "targetLowPrice": 15.9, "targetMeanPrice": 36.04, "targetMedianPrice": 41.73, "recommendationMean": 1.8, "recommendationKey": "buy", "numberOfAnalystOpinions": 5, "totalCash": 260992000, "totalCashPerShare": 4.148, "ebitda": -127251000, "totalDebt": 74465000, "quickRatio": 3.999, "currentRatio": 4.083, "totalRevenue": 4493000, "debtToEquity": 37.99, "revenuePerShare": 0.104, "returnOnAssets": -0.39571998, "returnOnEquity": -1.4541401, "freeCashflow": -57412876, "operatingCashflow": -97130000, "revenueGrowth": -0.001, "grossMargins": 1.0, "operatingMargins": -40.16793, "financialCurrency": "EUR", "trailingPegRatio": null, "__fetch_time": "2024-09-05"}]